
A smart investment strategy is to diversify your portfolio with both stable, established companies and growth stocks. Growth stocks, particularly those from the biotech industry, are often in the early stages of development. As a result, while these companies are risky, they also have more room for expansion. One such company is Skye Bioscience (SKYE), a clinical-stage biopharmaceutical company developing new therapeutic pathways for metabolic health.
Skye stock has earned a “Strong Buy” rating on Wall Street, with a forecast of over 500% upside from current levels. This optimistic outlook is primarily due to the company’s lead candidate nimacimab for obesity.